Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Alteryx Therapeutics Ltd in metadata) covers the quarter ended March 31, 2013. The registrant is an Australian biotechnology entity reporting under Rule 12g3-2(b). The filing includes an Appendix 4C Quarterly Report for entities admitted on the basis of commitments.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year to Date ($A'000) |
|---|---|---|
| Receipts from Customers | 0 | 0 |
| Net Operating Cash Flows | (551) | (5,103) |
| Net Investing Cash Flows | (6) | (16) |
| Net Financing Cash Flows | 883 | 8,721 |
| Net Increase in Cash | 326 | 3,602 |
| Cash at End of Period | 9,137 | 9,137 |
| Loan Facilities Available | 0 | 0 |
Revenue: The filing reports zero receipts from customers for both the current quarter and the year-to-date period.
Profit: The filing does not provide a clear value for net profit or loss, as the reconciliation of operating cash flows to operating profit is explicitly excluded from this report format.
Debt: No borrowings were repaid, and no loan facilities are currently available or used.
Material Changes and Unusual Items
- R&D Tax Concession: A significant cash inflow of $2,493,000 (quarterly) and $2,552,000 (year-to-date) was received from the Australian Taxation Office as an R&D Tax Concession Refund on March 27, 2013.
- Capital Raising: The company raised $883,000 in the current quarter and $8,821,000 year-to-date through the issue of shares and options. Capital raising costs of $437,000 were incurred year-to-date.
- Operating Expenditure: Research and development costs were $2,323,000 for the quarter and $5,402,000 year-to-date. Staff costs were $341,000 for the quarter.
- Non-Cash Transactions: 110,000 fully paid ordinary shares were issued to a consultant under the Employee Incentive Scheme and Consulting Agreement.
Guidance, Outlook, and Risks
The filing text does not provide specific forward-looking guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the standard compliance statements. The report focuses strictly on cash flow movements and financing activities.
Investor Verification Checklist
- Verify the company's current name status, as the metadata lists "Alteryx Therapeutics Ltd" while the filing text identifies "Prana Biotechnology Limited."
- Confirm the sustainability of the R&D Tax Concession refund as a primary source of operating cash flow given zero customer receipts.
- Review the dilution impact of the $8.8 million raised via share issuance year-to-date.
- Assess the burn rate relative to the $9.1 million cash balance to determine runway without further capital raises.